Cargando…

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities

Multiple myeloma (MM) is consistently preceded by precursor conditions recognized clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). We interrogate the whole genome sequence (WGS) profile of 18 MGUS and compare them with those from 14 SMMs and 80 MMs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oben, Bénedith, Froyen, Guy, Maclachlan, Kylee H., Leongamornlert, Daniel, Abascal, Federico, Zheng-Lin, Binbin, Yellapantula, Venkata, Derkach, Andriy, Geerdens, Ellen, Diamond, Benjamin T., Arijs, Ingrid, Maes, Brigitte, Vanhees, Kimberly, Hultcrantz, Malin, Manasanch, Elisabet E., Kazandjian, Dickran, Lesokhin, Alexander, Dogan, Ahmet, Zhang, Yanming, Mikulasova, Aneta, Walker, Brian, Morgan, Gareth, Campbell, Peter J., Landgren, Ola, Rummens, Jean-Luc, Bolli, Niccolò, Maura, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994386/ https://www.ncbi.nlm.nih.gov/pubmed/33767199 http://dx.doi.org/10.1038/s41467-021-22140-0

Ejemplares similares

The Dynamics of Nucleotide Variants in the Progression from Low–Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach
por: Oben, Bénedith, et al.
Publicado: (2022)

Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
por: Maclachlan, Kylee H., et al.
Publicado: (2021)

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients
por: Kazandjian, Dickran, et al.
Publicado: (2019)

Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations
por: Maclachlan, Kylee H., et al.
Publicado: (2022)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors
por: Froyen, Guy, et al.
Publicado: (2022)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
por: Shah, Urvi A., et al.
Publicado: (2021)

Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
por: Yellapantula, Venkata, et al.
Publicado: (2019)

Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma
por: Yellapantula, Venkata, et al.
Publicado: (2020)

P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS
por: Akhlaghi, T., et al.
Publicado: (2022)

Validation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors
por: Froyen, Guy, et al.
Publicado: (2016)

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
por: Huang, Phoebe A., et al.
Publicado: (2019)

Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
por: Fatoki, Raleigh Ayoolu, et al.
Publicado: (2022)

P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
por: Firestone, Ross, et al.
Publicado: (2023)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer
por: Kazandjian, Dickran, et al.
Publicado: (2016)

Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment
por: Oganesyan, Artem, et al.
Publicado: (2022)

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
por: Kazandjian, Dickran, et al.
Publicado: (2016)

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
por: Coffey, David G., et al.
Publicado: (2023)

Timing the initiation of multiple myeloma
por: Rustad, Even H., et al.
Publicado: (2020)

Raising to the Challenge: Building a Federated Biobank to Accelerate Translational Research—The University Biobank Limburg
por: Linsen, Loes, et al.
Publicado: (2019)

Accelerated single cell seeding in relapsed multiple myeloma
por: Landau, Heather J., et al.
Publicado: (2020)

Author Correction: Accelerated single cell seeding in relapsed multiple myeloma
por: Landau, Heather J., et al.
Publicado: (2021)

mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies
por: Rustad, Even H., et al.
Publicado: (2021)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma
por: Rustad, Even H., et al.
Publicado: (2019)

Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study
por: Korde, Neha, et al.
Publicado: (2023)

FROM BENIGN TO MALIGNANT DISEASE
por: Bolli, Niccolò
Publicado: (2022)

Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms
por: Gao, Qi, et al.
Publicado: (2018)

CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
por: Maura, Francesco, et al.
Publicado: (2020)

Pre-Diagnosis Dietary Patterns and Risk of Multiple Myeloma in the NIH-AARP Diet and Health Study
por: Castro, Francesca, et al.
Publicado: (2023)

Nutrition perceptions, needs and practices among patients with plasma cell disorders
por: Malik, Maria A., et al.
Publicado: (2022)

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
por: Korde, Neha, et al.
Publicado: (2021)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
por: Leleu, Xavier, et al.
Publicado: (2023)

Incidence patterns and review of Hodgkin lymphoma in the Republic of Armenia
por: Arakelyan, Jemma, et al.
Publicado: (2021)

The molecular pathogenesis of multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2020)

COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications
por: Vandekerckhove, Olivia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_57hajn1nu7qgkae7qo2a3db22n